Results 151 to 160 of about 371,009 (363)
STUDIES ON THE MECHANISM OF THE LUPUS ERYTHEMATOSUS (L.E.) PHENOMENON* [PDF]
, 1959 Alan C. Aisenberg
openalex +1 more source
DeckerMed Family Medicine, 2019 Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune illness characterized by autoantibodies directed at nuclear antigens that cause clinical and laboratory abnormalities, such as rash, arthritis, leukopenia and thrombocytopenia, alopecia, fever, nephritis, and neurologic disease.
Kyriakos A. Kirou, Michael D. Lockshin
openaire +1 more source
LP-126 The infectious complication in multitarget therapy of class V lupus nephritis: a case report
Lupus Science and Medicine, 2023 Anastasiia Shumilova +3 more
doaj +1 more source
Characterization of health concerns in people with neurofibromatosis type 1
Molecular Genetics &Genomic Medicine, Volume 11, Issue 1, January 2023., 2023 NF1 is a common cancer predisposition syndrome that requires lifelong surveillance. The aim of this research was to characterize health concerns and QoL in a population cohort. This study highlights that the presence of itch and increased visibility of NF1 complications impacts the QoL of adults and children.
Jane Fleming +4 more
wiley +1 more source
Phenome-wide causal proteomics enhance systemic lupus erythematosus flare prediction: A study in Asian populations [PDF]
arXivObjective: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by unpredictable flares. This study aimed to develop a novel proteomics-based risk prediction model specifically for Asian SLE populations to enhance personalized disease management and early intervention.
arxiv
A new and elementary proof of Newton's "favorite" quadrature formulae [PDF]
arXiv, 2007 In this note we shall give a new proof to a quadrature formulae due to Newton.
arxiv
A CYTOCHEMICAL STUDY OF THE L.E. BODIES OF SYSTEMIC LUPUS ERYTHEMATOSUS [PDF]
, 1957 Gabriel C. Godman, Arline D. Deitch
openalex +1 more source
LUPUS ERYTHEMATOSUS AND TUBERCULOSIS [PDF]
British Journal of Dermatology, 1895 n ...
openaire +3 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Riliprubart is a second‐generation, humanized immunoglobulin G4 that inhibits only the activated form of the C1s component of the proximal classical complement pathway. The clinical studies of riliprubart conducted thus far for the treatment of cold agglutinin disease (CAD), a rare autoimmune disease, include a Phase 1 first‐in‐human study in healthy ...
Timothy Chow +3 more
wiley +1 more source